Using the global gene computational network approach to infer potential enhancers of tumour response to anti-PD-1 therapies, Wu et al. have recently identified, in samples from patients with melanoma, GSK-3β inhibition as an approach likely to enhance anti-PD-1’s efficacy [40]. Here, PDCD1 is linked to melanoma.